Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology

被引:85
|
作者
D'Alto, Michele [1 ]
Romeo, Emanuele [1 ]
Argiento, Paola [1 ]
Sarubbi, Berardo [1 ]
Santoro, Giuseppe [1 ]
Grimaldi, Nicola [1 ]
Correra, Anna [1 ]
Scognamiglio, Giancarlo [1 ]
Russo, Maria Giovanna [1 ]
Calabro, Raffaele [1 ]
机构
[1] Univ Naples 2, Dept Cardiol, Monaldi Hosp, Naples, Italy
关键词
Pulmonary arterial hypertension; Congenital heart disease; Association therapy; IMPROVES FUNCTIONAL-CAPACITY; ORAL SILDENAFIL; COMBINATION THERAPY; INHALED ILOPROST; CLINICAL-TRIAL; ADULT PATIENTS; 6-MINUTE WALK; OPEN-LABEL; EFFICACY; TOLERABILITY;
D O I
10.1016/j.ijcard.2010.10.051
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The aim of the present study was to evaluate the safety, tolerability, clinical and haemodynamic impact of add-on sildenafil in patients with congenital heart disease (CHD)-related pulmonary arterial hypertension (PAH) and Eisenmenger physiology after failure of oral bosentan therapy. Methods: Thirty-two patients with CHD-related PAH (14 male, mean age 37.1 +/- 13.7 years) treated with oral bosentan underwent right heart catheterization (RHC) for clinical worsening. After RHC, all patients received oral sildenafil 20 mg thrice daily in addition to bosentan. Clinical status, resting transcutaneous oxygen saturation (SpO(2)), 6-minute walk test (6MWT), serology and RHC were assessed at baseline (before add-on sildenafil) and after 6 months of combination therapy. Results: Twelve patients had ventricular septal defect, 8 atrio-ventricular canal, 6 single ventricle, and 6 atrial septal defect. Twenty-eight/32 had Eisenmenger physiology and 4 (all with atrial septal defect) did not. All patients well tolerated combination therapy. After 6 months of therapy, an improvement in clinical status (WHO functional class 2.1 +/- 0.4 vs 2.9 +/- 0.3; P=0.042), 6-minute walk distance (360 +/- 51 vs 293 +/- 68 m; P=0.005), SpO(2) at the end of the 6MWT (72 +/- 10 vs 63 +/- 15%; P=0.047), Borg score (2.9 +/- 1.5 vs 4.4 +/- 2.3; P=0.036), serology (pro-brain natriuretic peptide 303 +/- 366 vs 760 +/- 943 pg/ml; P=0.008) and haemodynamics (pulmonary blood flow 3.4 +/- 1.0 vs 3.1 +/- 1.2 l/min/m(2), P=0.002; pulmonary vascular resistances index 19 +/- 9 vs 24 +/- 16 WU/m(2), P=0.003) was observed. Conclusions: Addition of sildenafil in adult patients with CHD-related PAH and Eisenmenger syndrome after oral bosentan therapy failure is safe and well tolerated at 6-month follow-up, resulting in a significant improvement in clinical status, effort SpO(2), exercise tolerance and haemodynamics. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:378 / 382
页数:5
相关论文
共 50 条
  • [1] Bosentan-sildenafil association in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology): safety, tolerability and clinical effect
    Romeo, E.
    D'Alto, M.
    Argiento, P.
    Sarubbi, B.
    Santoro, G.
    Scognamiglio, G.
    Alfano, D.
    D'Alterio, G.
    Russo, M. G.
    Calabro', R.
    [J]. EUROPEAN HEART JOURNAL, 2009, 30 : 901 - 901
  • [2] Bosentan therapy in patients with pulmonary hypertension secondary to congenital heart disease (Eisenmenger physiology)
    D'Alto, M
    Sarubbi, B
    Vizza, CD
    Romeo, E
    Santoro, G
    Argiento, P
    Russo, MG
    Calabrò, R
    [J]. CHEST, 2005, 128 (04) : 366S - 366S
  • [3] Treatment of Patients with Severe Pulmonary Arterial Hypertension Secondary to Congenital Heart Disease with Bosentan and Sildenafil
    Zhu, Xianyang
    Zhang, Duanzhen
    Meng, Jing
    Sheng, Xiaotang
    [J]. CIRCULATION, 2010, 122 (02) : E238 - E238
  • [4] How to evaluate patients with congenital heart disease-related pulmonary arterial hypertension
    Ntiloudi, Despoina
    Zanos, Stavros
    Gatzoulis, Michael A.
    Karvounis, Haralambos
    Giannakoulas, George
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2019, 17 (01) : 11 - 18
  • [5] Long term effects of bosentan treatment in adult patients with pulmonary arterial hypertension related to congenital heart disease (Eisenmenger physiology):: safety, tolerability, clinical, and haemodynamic effect
    D'Alto, M.
    Vizza, C. D.
    Romeo, E.
    Badagliacca, R.
    Santoro, G.
    Poscia, R.
    Sarubbi, B.
    Mancone, M.
    Argiento, P.
    Ferrante, F.
    Russo, M. G.
    Fedele, F.
    Calabro, R.
    [J]. HEART, 2007, 93 (05) : 621 - 625
  • [6] Combination Of Sildenafil To Bosentan Therapy In Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Defects
    Beciani, E.
    Leci, E.
    Palazzini, M.
    Bachetti, C.
    Sciarra, F.
    Conficoni, E.
    Manes, A.
    Galie, N.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [7] Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
    Skoro-Sajer, Nika
    Gerges, Christian
    Balint, Olga Hajnalka
    Kohalmi, Dora
    Kaldararova, Monika
    Simkova, Iveta
    Jakowitsch, Johannes
    Gabriel, Harald
    Baumgartner, Helmut
    Gerges, Mario
    Sadushi-Kolici, Roela
    Celermajer, David S.
    Lang, Irene Marthe
    [J]. HEART, 2018, 104 (14) : 1195 - 1199
  • [8] Multimodality imaging in congenital heart disease-related pulmonary arterial hypertension
    D'Alto, Michele
    Dimopoulos, Konstantinos
    Budts, Werner
    Diller, Gerhard-Paul
    Di Salvo, Giovanni
    Dellegrottaglie, Santo
    Festa, Pierluigi
    Scognamiglio, Giancarlo
    Rea, Gaetano
    Ali, Lamia Ait
    Li, Wei
    Gatzoulis, Michael A.
    [J]. HEART, 2016, 102 (12) : 910 - U118
  • [9] Pulmonary arterial hypertension treatment with bosentan in pediatric patients with congenital heart disease
    Romero Jimenez, Rosa M.
    Garcia Sanchez, Raquel
    Gimenez Manzorro, Alvaro
    Martinez Fernandez-Llamazares, Cecilia
    Sanjurjo Saez, Maria
    [J]. PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 347 - 347
  • [10] Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease
    Benza, RL
    Rayburn, BK
    Tallaj, JA
    Coffey, CS
    Pinderski, LJ
    Parnoukian, SV
    Bourge, RC
    [J]. CHEST, 2006, 129 (04) : 1009 - 1015